Mercedon 2020 earnings: China's results led global K drug sales by nearly $15 billion

On February 04, 2021, Global Head MNC companies Mercado, Roche, Shishi Shiguibao and Gilead announced their fourth-quarter results on the same day, and the article will first introduce the sales data, research and development and regulatory progress of Mercado's key products.
written at the beginning of the article, of course, should be PD-(L)1 monoantimmune market, in 2020, PD-(L) 1 monoantigen market is expected to exceed $26 billion, since 2014, after 7 years of development, PD-(L) 1 monoantigen represented by tumor immunity has changed the standard treatment of many diseases, become a variety of diseases The cornerstone therapy, it is clear that the competitive landscape of a variety of advanced tumors has been basically clear, at present, a number of PD-(L)1 mono-resistance are constantly exploring the competition for early-stage tumors, in a growing PD-(L)1 mono-resistance, Odivo took the lead in the decline, sales in 2020 $6.992 billion, down 2.94% YoY!Note: In U.S. dollars at the average annual exchange rate; Dvaliyu monolith sales forecast for the fourth quarter of 2020 I. Mercadon has become a unique "K" company On February 04, 2021, Merck and Co., Inc.) reported full-year revenue of $48 billion, up 2% YoY, pharmaceutical revenue of $43 billion and animal health revenue of $4.703 billion. In 7 years, Corida has become a nearly $15 billion super-heavy drug, contributing 33% of the pharmaceutical business;
is also remarkable that Mercedon's research and development spending will jump 37% in 2020, from $9,872 million to $13,558 million! Four key businesses supporting growth: Oncology, Vaccines, Hospital, Animal Health Mercedon Mercedon Global Results: China continues to lead the global Merca East Mercadon 2020 earnings report with the following focus: 1.PD1-PDL1 fully opened up the era of tumor immunity, but Rida is one of the most concerned super-heavyweight varieties, into the tens of billions of dollars family, a few large varieties "Corada has achieved overall success in advanced cancers (especially non-small cell lung cancer) and has made significant explorations in the clinical benefits of cancer immunotherapy for a wide range of cancers; 2. In the oncology business, Olapali and Lunvatinie combined to promote revenue of approximately US$1.6 billion, up more than 50% year-on-year, while the joint programmes of Olapali, Lenvatini and Paboliju monoantitor are also being explored; 3. In the vaccine business, Jiadasso/Jiadasso 9 cervical cancer vaccine is the most important variety, but the most noteworthy is still the new generation of pneumonia vaccine V114, Once it can take a dominant position in the bacterial pneumonia vaccine market, this will be a new growth point in the future; there has been no significant progress on the new coronavirus, such as the termination of the V590/V591 project; and Mercadon is still advancing CD24Fc and Mmolnupiravir in the development of treatment options.
2. In just seven years since its listing, Therida has sold nearly $15 billion and there are still a number of significant regulatory or project developments in the U.S. by 2020, such as: 1. CPS ≥ late-stage, non-removable breast cancer; 2. Due to the excellent data of KEYNOTE-204, Rhida's clinical status in classic Hodgkin's lymphoma continues to improve; 3. Late-stage non-removable metastatic gastric cancer, first-line therapy for gastroesophageal junction cancer filed for market, PDUFA date is April 18, 2021; and 4. Project Progress, Corida combined chemotherapy, confirmed clinical benefits in patients with early triple negative breast cancer.
is no longer mentioned here in other regulatory developments in 2020 and in key Phase 3 clinical developments.
Keytruda has shown effectiveness in up to 25 tumor species, and the drug (single-drug/combination) has now won 17 of them, whether first-line or non-first-line therapies.
, the advantages of corida in lung cancer, especially non-small cell lung cancer, lay an important foundation for the strong growth of the drug.
, which covers 17 cancers and more than 20 adaptive disorders, will be the main direction of Nerida's adaptation expansion in the coming years, with the 2019 results revealing the regulatory development expectations for the next few years However, only KEYNOTE-054 and KEYNOTE-522 have published data, of which the approval of three-yin breast cancer-assisted treatment is 2 years slower than expected, other early indications-assisted/new complementary treatment options will be significantly behind expectations!III. Under the great aura of "K", the vaccine business (especially Jiadashu 9) is still one of the traditional businesses of Mercadon, and the steady Jiadashu/Jiadashu 9 continues to contribute cash flow steadily to Mercedon, with sales of US$3.938 billion in 2020, up 5% YoY.
Mercado's future vaccine is expected to be mostly on the bacterial pneumonia prevention vaccine, as the listed variety Pneumovax 23 does not touch the population under 2 years of age, so in the competition with Pye 13, Mercado in the development of a new generation of upgraded varieties V11 4, including Pyeel 13 all serum type and 22F, 33F new serum type, has also announced a number of adult patients over 18 years of age in the protection effect, the future of its vaccine protection in young children worthy of long-term attention, the current V114 listing application has been accepted!4. Three major acquisitions of Merca East in 2020, including the New Crown Project and the Tumor Project Mercedon K Pharmaceuticals, have undoubtedly become one of Merca East's most important development directions, occupying many of Merca East's resources! Mercedon's research and development investment is also growing rapidly, with $10.3 billion, $9.8 billion, $9.9 billion and $13.6 billion in 2017, 2018, 2019 and 2020, respectively.
2020 acquisition: 1. OncoImmune acquires new coronavirus treatment program, CD24Fc; VelosBio acquires a RUR1 antibody association drug to continue to strengthen the oncology business; Themis Bioscience acquisition, which included a new coronavirus prevention vaccine, has been terminated.
what deserves attention in 2021, to put it simply: 1. Pabli Pearl Monoanti-Levatini-Olapali breakthrough in broader indications and, more importantly, Pablic Pearl Monoanti in early cancer-assisted/new-assisted treatments, such as KEYNOTE-091 is expected to be disclosed in 2021; 2.V114 Next-generation bacterial pneumonia vaccine, which has been submitted for market, deserves close attention, and future data on the effectiveness of its early childhood protection is critical, PDUFA date July 18, 2021.